Benefit of adding pioglitazone to successful statin therapy in nondiabetic patients with coronary artery disease

Circ J. 2008 Jul;72(7):1193-7. doi: 10.1253/circj.72.1193.

Abstract

Background: Pioglitazone added to successful statin therapy may be beneficial for coronary artery disease (CAD) patients without diabetes mellitus.

Methods and results: Fourteen individuals optimally treated with statin for >6 months were randomized to a pioglitazone or control group. Pioglitazone significantly improved insulin resistance, reduced high-sensitivity C-reactive protein, increased high-molecular-weight adiponectin and high-density lipoprotein cholesterol levels. Ultrasound echogenicity of carotid atheroma assessed by integrated backscatter was significantly increased by pioglitazone and correlated with adiponectin levels.

Conclusion: Adding pioglitazone to successful statin therapy may be an effective therapeutic strategy for patients with CAD.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiponectin / blood
  • Adiponectin / chemistry
  • Aged
  • C-Reactive Protein / metabolism
  • Carotid Artery Diseases / diagnostic imaging
  • Carotid Artery Diseases / drug therapy
  • Cholesterol, HDL / blood
  • Coronary Artery Disease / drug therapy*
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
  • Hypoglycemic Agents / administration & dosage*
  • Insulin Resistance
  • Male
  • Middle Aged
  • Molecular Weight
  • Pioglitazone
  • Thiazolidinediones / administration & dosage*
  • Treatment Outcome
  • Ultrasonography

Substances

  • ADIPOQ protein, human
  • Adiponectin
  • Cholesterol, HDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypoglycemic Agents
  • Thiazolidinediones
  • C-Reactive Protein
  • Pioglitazone